Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 31, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2020.115953
Keywords
Androgen receptor; Novel thiohydantoin derivatives; Androgen receptor antagonists; Prostate cancer
Funding
- National Natural Science Foundation of China [82073684]
Ask authors/readers for more resources
Prostate cancer is the most common malignancy in men worldwide. In this study, novel thiohydantoin derivatives of enzalutamide were designed and synthesized, with compound 31c identified as a more potent AR antagonist than enzalutamide. The data suggest that 31c could be a promising lead compound for the treatment of prostate cancer.
Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available